Post Profile

No silver lining in failed Bristol cancer drug trial

COPENHAGEN (Reuters) - Bristol-Myers Squibb disappointed investors on Sunday as researchers detailed data for its Opdivo cancer immunotherapy, which was already known to have failed to do better than older chemotherapies in a closely watched clinical trial.
read more


Related Posts

Lung cancer doctors eye Merck's Keytruda over Bristol's Opdivo

Health : Reuters: Health

(Reuters) - Recent clinical trial results are likely to lead doctors to treat more patients who have a common form of lung cancer with a Merck drug at the expense of a Bristol-Myers Squibb medication at least until more data emerges...

Bristol-Myers to test Opdivo with Nektar drug for several cancers

Health : Reuters: Health

(Reuters) - Bristol-Myers Squibb Co said on Tuesday it would evaluate the use of its blockbuster cancer immunotherapy Opdivo in combination with an experimental drug from Nektar Therapeutics to treat multiple cancers.

Bristol-Myers shares are bombing after a failed study — and its biggest rival is surging (BMY, MRK)

Business & Finance : Business Insider: Clusterstock

Shares of Bristol-Myers Squibb were hit hard Friday after news that its blockbuster cancer drug failed a key clinical trial. The drug, called Opdivo, is one of a new set of drugs called immunotherapy. The drug targets the programmed...

Bristol's Opdivo Disappoints in Lung Cancer, While Merck's Keytruda Surprises

Business & Finance : Forbes: Business

FindTheCompany | Graphiq Shares of Bristol-Myers Squibb have fallen 26% since August, when a large study of lung cancer patients failed to demonstrate that its breakthrough cancer drug, Opdivo, could slow tumor growth or extend pati...

Bristol drug flop opens big cancer opportunity: AstraZeneca CEO

Health : Reuters: Health

COPENHAGEN (Reuters) - The failure of Bristol-Myers Squibb's blockbuster Opdivo immunotherapy in previously untreated lung cancer patients has opened up the market for AstraZeneca, its chief executive believes.


Copyright © 2016 Regator, LLC